Bristol Myers Squibb reported better-than-expected earnings for the first quarter and boosted its outlook while noting the ...

Investing.com -- Bristol-Myers Squibb (NYSE: BMY) reported first quarter earnings that surpassed analyst expectations, driven ...

Bristol Myers Squibb Co. raised its sales and profit forecasts for the year on better-than-expected sales of older drugs and ...

The guidance revisions include the estimated impact of current tariffs on U.S. products shipped to China, but not Trump’s ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

In the phase III ARISE trial, adjunctive xanomeline and trospium chloride (Cobenfy) were no better than placebo at improving ...

This was a low-key week for the biotech sector before the onset of the first-quarter earnings season. Biotech giant Bristol Myers Squibb BMY was down on data from the schizophrenia study while ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

U.S. stock indexes rallied at midday Wednesday as President Donald Trump said he has "no intention" of firing Federal Reserve ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy ...